| 臺大學術典藏 |
2020-04-10T12:51:03Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Chiun Hsu; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-09T09:43:08Z |
Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer
|
Wei, C. H.; Liang, Y. H.; Hsu, W. H.; Shao, Y. Y.; Lin, Y. C.; Chou, P. C.; Cheng, A. L.; Yeh, K. H. |
| 臺大學術典藏 |
2020-04-09T09:42:28Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao, Y.-Y.; Shau, W.-Y.; Chan, S.-Y.; Lu, L.-C.; Hsu, C.-H.; Cheng, A.-L. |
| 臺大學術典藏 |
2020-04-09T09:40:50Z |
Influence of age on opioid prescription of patients with advanced lung cancer
|
Shao, Y. Y.; Lin, C. P.; Chen, H. M.; Lee, H. S. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-04-09T09:31:03Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Shao, Y. Y.; Lin, C. P.; Hsu, C. H.; Fu, W. M.; Chen, H. M.; Lee, Y. H.; Lai, M. S. |
| 臺大學術典藏 |
2020-03-23T07:19:27Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; Lee W.-C.; Hsu C.; CHIUN-SHENG HUANG; Liau J.-Y.; Lu Y.-S.; Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Chiun-Sheng Huang;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2020-03-07T06:42:17Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.;Kuan-Ting Kuo;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; KUAN-TING KUO; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
|
Lu L.-C.; Shao Y.-Y.; Lee Y.-H.; MIN-SHU HSIEH; Hsiao C.-H.; Lin H.-H.; Kao H.-F.; Ma Y.-Y.; Yen F.-C.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-03-05T08:03:56Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Hsu C.-H.; Huang T.-C.; Shao Y.-Y.; Lien M.-Y.; Kuo H.-Y.; MIN-SHU HSIEH; Lin C.-Y.; Lin C.-C.; Guo J.-C.; Guo J.-C.;Lin C.-C.;Lin C.-Y.;Min-Shu Hsieh;Kuo H.-Y.;Lien M.-Y.;Shao Y.-Y.;Huang T.-C.;Hsu C.-H. |
| 臺大學術典藏 |
2020-03-05T07:52:40Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; KUAN-TING KUO; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-05T06:28:44Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Hsu C.; Lee W.-C.; JAU-YU LIAU; Huang C.-S.; Lu Y.-S.; Kuo K.-T.; Hu F.-C.; Shao Y.-Y.; Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Jau-Yu Liau;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-20T06:53:16Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Liang P.-C.; YU-WEN TIEN |
| 臺大學術典藏 |
2020-02-19T09:33:50Z |
Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma
|
Shao Y.-Y.; Chen C.-L.; MING-CHIH HO; Huang C.-C.; Tu H.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-02-19T09:33:45Z |
Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
|
Shao Y.-Y.; MING-CHIH HO; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-02-14T02:49:54Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; WEN-FANG CHENG; Lin Y.-L.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-02-11T07:58:41Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.;Liang P.-C.;Yao-Ming Wu;Huang C.-C.;Huang K.-W.;Cheng J.C.;Hsu C.-H.;Hsu C.;Cheng A.-L.;Lin Z.-Z.; Shao Y.-Y.; Liang P.-C.; YAO-MING WU; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-02-10T09:00:19Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Yeh C.-C.;Hsu C.-H.;Shao Y.-Y.;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.; Yeh C.-C.; Hsu C.-H.; Shao Y.-Y.; Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.; MONG-HSUN TSAI |
| 臺大學術典藏 |
2020-02-06T05:22:05Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Cheng A.-L.; Yeh K.-H.; WEN-FANG CHENG; Lin Y.-L.; Hsu C.; Hsu C.-H.; Shao Y.-Y.; Lu L.-C.; Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; WEN-FANG CHENG; Hsu C.; Yeh K.-H.;Cheng A.-L.;Lin Y.-L.;WEN-FANG CHENG;Hsu C.;Hsu C.-H.;Shao Y.-Y.;Lu L.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H. |
| 臺大學術典藏 |
2020-02-06T05:21:56Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Lai M.-S.;Yang J.C.H.;Cheng A.-L.;WEN-FANG CHENG;Hsu C.;Shao Y.-Y.;Yang Y.-Y.;Lai C.-L.;Shau W.-Y.;Kuo R.;Lin Z.-Z.;Kuo H.-Y.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; WEN-FANG CHENG; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-01-22T04:47:49Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Yeh C.-C.;Hsu C.-H.;Shao Y.-Y.;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Lu-Ping Chow; Yeh C.-C.; Hsu C.-H.; Shao Y.-Y.; Ho W.-C.; Tsai M.-H.; Feng W.-C.; LU-PING CHOW |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 國立成功大學 |
2020 |
Satisfaction with pain management and impact of pain on quality of life in cancer patients
|
Lin, J.;Hsieh, R.-K.;Chen, J.-S.;Lee, K.-D.;Rau, K.-M.;Shao, Y.-Y.;Sung, Y.-C.;Yeh, S.-P.;Chang, Chang C.-S.;Liu, T.-C.;Wu, M.-F.;Lee, M.-Y.;Yu, M.-S.;Yen, C.-J.;Lai, P.-Y.;Hwang, W.-L.;Chiou, T.-J. |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
